In addition, the article discusses novel therapies, including Bruton’s tyrosine kinase inhibitors, BCL-2 inhibitors, ROR1 inhibitors, and bispecific T-cell engagers, which could become cornerstones of MCL treatment in the future. Here, ROR1 is linked to mantle cell lymphoma.